In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on MyoKardia Inc (MYOK), with a price target of $90. The company’s shares closed on Friday at $49.67.
According to TipRanks.com, Young is a 4-star analyst with an average return of 7.7% and a 46.8% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.
Currently, the analyst consensus on MyoKardia Inc is a Strong Buy with an average price target of $78.71, which is a 58.5% upside from current levels. In a report issued on March 4, BMO Capital also maintained a Buy rating on the stock with a $90 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.79 and a one-year low of $39.01. Currently, MyoKardia Inc has an average volume of 503.7K.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.
